Cogstate Limited (CGS) Earnings Call Transcripts

Cogstate Limited's Latest Earnings Call - June 9, 2026

In the June quarter of the 2026 fiscal year, Cogstate Limited reported strong momentum in sales, with total contracts executed reaching $67.1 million, marking it as the company's second-best year on record with a quarter still to report. The company highlighted a significant diversification strategy, with $23.7 million (35%) of sales contracts coming from mood, sleep, and other neurological conditions, up from $8.5 million in FY 2025. Management expressed confidence in sustaining growth in new areas such as psychiatry and narcolepsy, driven by strategic partnerships and innovative service offerings.

Reported metrics

Guidance from management

Management expressed confidence in sustaining growth in psychiatry and narcolepsy markets, indicating a strong pipeline and commitment to innovation. They expect to report strong results for the June quarter on July 8, 2026.

What management said

I think it's -- you just need to look at the X-axis. I think the previous demonstration of this was a quarterly presentation of the data, and this is just a half yearly. So the fact that it's basically a doubling is just that it's 2 quarters. I think that's all that's going on there. So apologies for confusing people by changing the access.

Yes. I think this is a really interesting thing. And Paul, I'll come to you in a second to talk about the measurement of cognition in narcolepsy outside of clinical trials. But I think there is an opportunity. And I think one of the things that and particularly the Paul's done a fantastic job of and the whole science team is positioning the Cogstate digital assessments as key or primary cognitive endpoints in these t...

What analysts pressed on

Analysts raised concerns about the competitive landscape in psychiatry and narcolepsy, questioning whether Cogstate can maintain its growth trajectory amidst established players. There were also inquiries about the conversion rates of large channel partner pipelines, indicating uncertainty in sales execution.

Main topics on the call

• Strong Sales Momentum — Cogstate's total sales contracts executed through the first nine months of FY 2026 reached $67.1 million, positioning the company for a strong finish to the fiscal year. CEO Brad O'Connor stated, "We're seeing sales mome...
• Diversification into New Indications — Management reported that 35% of sales contracts were derived from mood, sleep, and neurological conditions, a significant increase from previous years. O'Connor noted, "We're seeing that diversification into different in...
• Expansion of Centralized Rating Services — Cogstate is enhancing its service delivery through centralized rating, which allows for more consistent assessments in clinical trials. Rachel Colite emphasized that this shift "improves the consistency of delivery, all ...
• Growth in Psychiatry and Narcolepsy Markets — The company is experiencing growth in psychiatry trials, which are expanding at 8% to 10% annually. O'Connor confirmed that they are "really just getting started there in terms of that growth profile," highlighting the p...

Read the full Cogstate Limited transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 20 Cogstate Limited earnings call transcripts on record, spanning July 23, 2020 to June 9, 2026. Based on this history, Cogstate Limited reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CGS

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Health Care Technology

Calls on record

20

First call

July 23, 2020

Most recent

June 9, 2026

Reporting cadence

quarterly